LUMACAFTOR AND IVACAFTOR and CYSTIC FIBROSIS RESPIRATORY INFECTION SUPPRESSION

Overview

CYSTIC FIBROSIS RESPIRATORY INFECTION SUPPRESSION is the #18 most commonly reported adverse reaction for LUMACAFTOR AND IVACAFTOR, manufactured by Vertex Pharmaceuticals Incorporated. There are 162 FDA adverse event reports linking LUMACAFTOR AND IVACAFTOR to CYSTIC FIBROSIS RESPIRATORY INFECTION SUPPRESSION. This represents approximately 1.3% of all 12,020 adverse event reports for this drug.

Patients taking LUMACAFTOR AND IVACAFTOR who experience cystic fibrosis respiratory infection suppression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

CYSTIC FIBROSIS RESPIRATORY INFECTION SUPPRESSION is a less commonly reported adverse event for LUMACAFTOR AND IVACAFTOR, but still significant enough to appear in the safety profile.

Other Side Effects of LUMACAFTOR AND IVACAFTOR

In addition to cystic fibrosis respiratory infection suppression, the following adverse reactions have been reported for LUMACAFTOR AND IVACAFTOR:

• INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS — 1,460 reports
• HOSPITALISATION — 885 reports
• DYSPNOEA — 555 reports
• PULMONARY FUNCTION TEST DECREASED — 396 reports
• COUGH — 391 reports
• INFECTION — 369 reports
• CHEST DISCOMFORT — 343 reports
• CYSTIC FIBROSIS — 325 reports
• PNEUMONIA — 268 reports
• MALAISE — 224 reports

Other Drugs Associated with CYSTIC FIBROSIS RESPIRATORY INFECTION SUPPRESSION

The following drugs have also been linked to cystic fibrosis respiratory infection suppression in FDA adverse event reports:

Does LUMACAFTOR AND IVACAFTOR cause CYSTIC FIBROSIS RESPIRATORY INFECTION SUPPRESSION?

CYSTIC FIBROSIS RESPIRATORY INFECTION SUPPRESSION has been reported as an adverse event in 162 FDA reports for LUMACAFTOR AND IVACAFTOR. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is CYSTIC FIBROSIS RESPIRATORY INFECTION SUPPRESSION with LUMACAFTOR AND IVACAFTOR?

CYSTIC FIBROSIS RESPIRATORY INFECTION SUPPRESSION accounts for approximately 1.3% of all adverse event reports for LUMACAFTOR AND IVACAFTOR, making it a notable side effect.

What should I do if I experience CYSTIC FIBROSIS RESPIRATORY INFECTION SUPPRESSION while taking LUMACAFTOR AND IVACAFTOR?

If you experience cystic fibrosis respiratory infection suppression while taking LUMACAFTOR AND IVACAFTOR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages